Pioneers in Biotechnology Asset Management

For over thirty years at the forefront of financial innovation, J. Lamarck embodies a forward-thinking investment philosophy that evolves in step with market dynamics and emerging opportunities.

J. Lamarck Asset Management S.A., a Swiss financial company authorised under the Collective Investment Schemes Act (LiCol) with a FINMA license, leverages thirty years of deep knowledge, expertise and experience in the healthcare, pharmaceutical and biotechnology sectors to deliver wealth management and fund management solutions that place long-term value creation for the client at the very core.

Its investment philosophy is built on active, disciplined management, with rigorous attention to the quality of selected assets and full alignment with each client’s objectives.

Today, more than ever, the ability to interpret major macro shifts – environmental, geopolitical, technological and demographic – represents a strategic advantage. For this reason, J. Lamarck Asset Management adopts a conscious, long-term-oriented approach that can identify real opportunities even in complex scenarios.

With a proven track record of more than thirty years successfully navigating economic cycles – from the dot-com boom to the rise of green finance – J. Lamarck’s strategies have consistently delivered compelling risk-adjusted returns.

Visit the website